Confronto

Maridebart Cafraglutide vs. Petrelintide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Maridebart Cafraglutide	Petrelintide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Maridebart Cafraglutide

Voce completa →

Petrelintide

Voce completa →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?: Maridebart Cafraglutide is classified as "Metabolico", while Petrelintide is classified as "Metabolico". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?: The highest available evidence level is "RCT sull'uomo" for Maridebart Cafraglutide and "RCT sull'uomo" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?: Germania: Maridebart Cafraglutide — Non approvato, Petrelintide — Non approvato. Stati Uniti: Maridebart Cafraglutide — Non approvato, Petrelintide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Petrelintide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?

Maridebart Cafraglutide is classified as "Metabolico", while Petrelintide is classified as "Metabolico". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?

The highest available evidence level is "RCT sull'uomo" for Maridebart Cafraglutide and "RCT sull'uomo" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?

Germania: Maridebart Cafraglutide — Non approvato, Petrelintide — Non approvato. Stati Uniti: Maridebart Cafraglutide — Non approvato, Petrelintide — Non approvato. These are factual summaries with source and review date on the individual pages.